Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Orphan drugs: creating a policy

C H Asbury, P D Stolley

    Annals of Internal Medicine
    |August 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Developing medically important but commercially unprofitable orphan drugs presents a challenge. Policy recommendations aim to incentivize industry collaboration for orphan drug development and accessibility.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women.

    Cancer causes & control : CCC·2001
    Same author

    Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U.S. women.

    The Journal of nutrition·2001
    Same author

    Alcohol intake, type of beverage, and the risk of cerebral infarction in young women.

    Stroke·2001
    Same author

    Phenolphthalein laxatives and risk of cancer.

    Journal of the National Cancer Institute·2000
    Same author

    Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States).

    Cancer causes & control : CCC·2000
    Same author

    A case-control study of analgesic use and ovarian cancer.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2000

    Area of Science:

    • Health Economics
    • Pharmaceutical Policy
    • Drug Development

    Background:

    • Medically vital drugs often lack commercial viability in free market economies.
    • This creates a significant challenge in ensuring patient access to necessary treatments.
    • Orphan drugs, crucial for rare diseases, exemplify this issue.

    Purpose of the Study:

    • To analyze the complexities surrounding the development and accessibility of orphan drugs.
    • To evaluate the implications of proposed federal policies for orphan drug development.
    • To underscore the need for a comprehensive understanding before policy implementation.

    Main Methods:

    • Review of existing literature on orphan drug challenges.
    • Analysis of federal government initiatives and task force recommendations.

    Related Experiment Videos

  • Examination of the economic and regulatory landscape for pharmaceuticals.

    • Main Results:

    • Federal Interagency Task Force proposes administrative and legislative changes.
    • Recommendations aim to create incentives for industry-government cooperation.
    • A clearer understanding of interconnected orphan drug problems is deemed necessary.

    Conclusions:

    • Proposed policies represent a first step in addressing orphan drug scarcity.
    • Interactive planning among diverse stakeholders is crucial for effective policy.
    • Achieving desired outcomes requires collaborative strategy development for orphan drug access.